Abstract
Just over 50% of patients with advanced rectal cancer have a poor response to chemoradiotherapy with resultant poor outcomes. Professor Glimelius reviews the evidence base for defining such patients and the potential role, if any, of further treatment.
Cite
CITATION STYLE
APA
Bhoday, J., Glimelius, B., Tait, D., Glynne-Jones, R., Adams, R., & Brown, G. (2018). Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on? Colorectal Disease, 20, 97–99. https://doi.org/10.1111/codi.14088
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free